2-Aminoindane
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2-AI (2-aminoindane) is a synthetic stimulant of the aminoindane class. It is a conformationally restricted structural analog of amphetamine, distinguished by its short duration and noradrenergic selectivity.[1] 2-AI is a selective norepinephrine releasing agent, producing its effects by triggering reverse transport of norepinephrine into the synaptic cleft.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, methylphenidate, cathinones +1 moreamphetamine, methylphenidate, cathinones, other NET-releasing agents show less
2-AI was first characterized in 1990 by David E. Nichols at Purdue University as part of a program to develop non-neurotoxic analogs of MDMA.[1] The compound entered recreational markets around 2010 following the UK ban on mephedrone and synthetic cathinones.[3] It remains an uncommon research chemical with no approved medical use and limited recreational prevalence.
Subjective effects include physical stimulation, wakefulness, appetite suppression, and cognitive activation.[4] The experience is one of clean noradrenergic drive — functional alertness without the emotional warmth of entactogens or the euphoria of dopaminergic stimulants. Irritability, cognitive fatigue, and depressed mood during the comedown are common unsought effects.
No physical dependence data exist; weak DAT activity predicts lower reinforcing potential than amphetamine.[2] The primary risk is cardiovascular — norepinephrine release drives sympathomimetic strain, the short duration encourages compulsive redosing, and genetic variation in the NAT2 enzyme may amplify exposure in a significant fraction of users.[5][6] No controlled human studies have been published; the current understanding rests on in vitro pharmacology, computational toxicity models, and user reports.
History[edit]
Discovery
The aminoindane scaffold entered psychopharmacology through David E. Nichols and colleagues at Purdue University. In 1990, the group published a study of cyclic analogs of MDA, including unsubstituted 2-aminoindane and its methylenedioxy derivative MDAI.[1] The goal was to identify compounds retaining MDMA's therapeutic properties without its serotonergic neurotoxicity. 2-AI did not substitute for MDMA in drug-discrimination tests, establishing from the outset that it lacked entactogenic character.[1]
Research trajectory
Through the 1990s, the Nichols group continued aminoindane research — Johnson et al. examined serotonin neurotoxicity interactions involving MDAI,[7] and Sprague et al. used MDAI to probe mechanisms of neurotoxicity.[8] These studies established MDAI as a valuable research tool, but 2-AI itself attracted little further attention. Earlier interest in aminoindane derivatives during the 1970s had focused on potential bronchodilating and analgesic properties.[3]
Market emergence
When the UK banned mephedrone and synthetic cathinones in April 2010, aminoindanes filled part of the resulting market gap.[9][3] 2-AI appeared alongside MDAI, 5-IAI, and MMAI as a research chemical, identified by Sainsbury et al. as a conformationally restricted amphetamine analog.[10] User reports positioned it as a short-acting stimulant comparable to benzylpiperazine — a distinctly different profile from MDAI's empathogenic character.[4]
The name 2-aminoindane derives from the compound's structure: an amine group at the 2-position of the indane (2,3-dihydroindene) ring system. The abbreviation 2-AI is standard in both research and market contexts. Unlike MDAI, which developed a distinct identity in online drug communities as an empathogen, 2-AI never acquired a cultural presence beyond the research chemical niche — its short duration and purely stimulant profile limited its appeal relative to longer-acting or more hedonic alternatives.
Chemistry[edit]
Structural class
2-Aminoindane belongs to the aminoindane chemical family, a subclass of phenethylamines in which the flexible sidechain is locked into a rigid bicyclic indane ring. The amine sits at C2 of the five-membered ring, making 2-AI a rigid analog of amphetamine — the indane scaffold fixes the sidechain geometry and limits rotational freedom.[10]
The unsubstituted 2-AI scaffold serves as the parent compound for the aminoindane class. Ring substitution at the 5- and 6-positions profoundly alters pharmacology: adding a methylenedioxy group yields MDAI, shifting selectivity from the NET to the SERT.[11] Other derivatives include 5-IAI, MMAI, and MEAI.
Molecular properties
| Molecular formula | C₉H₁₁N |
| Molecular weight | 133.19 g/mol |
The molecule consists of a benzene ring fused to a cyclopentane ring bearing a primary amine at the 2-position. Among psychoactive phenethylamine derivatives, 2-AI is one of the simplest.
Stereochemistry
2-AI is achiral. The C2 carbon bearing the amine is flanked symmetrically by two methylene bridges connecting to the same aromatic ring, creating a plane of symmetry. No stereoisomers exist — distinguishing 2-AI from amphetamine, which has a chirality center and exists as R- and S-enantiomers with differing pharmacological profiles.
Physical properties
The free base has a melting point of 33–34 °C, meaning it exists as a liquid at typical room temperature.[12] The hydrochloride salt is a solid more suitable for handling and storage. The predicted pKa of 9.21 indicates a strongly basic amine at physiological pH, consistent with protonation in biological fluids and membrane permeability of the free base.
Pharmacology[edit]
Mechanism of action
2-AI acts as a substrate-type norepinephrine releasing agent. It enters presynaptic nerve terminals through the NET (NET) and triggers reverse transport of stored norepinephrine into the synaptic cleft.[2] This is distinct from reuptake inhibitor — rather than blocking the transporter, 2-AI passes through it and forces norepinephrine out.
Activity at the DAT is weak, and SERT engagement is negligible.[2] This selectivity profile explains why 2-AI produces physical stimulation without the emotional warmth of serotonin-active compounds like MDAI or the pronounced euphoria of dopamine-active stimulants like amphetamine.
A secondary pharmacological feature is 2-AI's binding at α₂-adrenoceptors.[11] These receptors act as presynaptic brakes on norepinephrine release — a feedback mechanism that may self-limit the stimulant and cardiovascular effects. Whether 2-AI activates or blocks these receptors remains unknown, and the functional consequence has not been determined.[11]
Pharmacokinetics
No human pharmacokinetic data have been published for 2-AI.
In vitro studies using human liver preparations found that 2-AI resists the oxidative metabolism typical of most stimulants. Instead, it is cleared exclusively by NAT2 acetylation — a pathway with significant genetic variation.[6] Approximately 40–60% of Caucasian populations are slow NAT2 acetylators, meaning they break down 2-AI more slowly and may experience higher blood levels from the same dose.
2-AI is also the primary active metabolite of N-methyl-2-aminoindane (NM-2-AI), produced when the body removes the methyl group.[13] Users of NM-2-AI are therefore exposed to 2-AI whether they intend it or not.
The short subjective duration of 1–2 hours is consistent with rapid clearance observed across the aminoindane class. Related compounds show high brain penetration, peak levels within 30 minutes, and near-complete clearance within hours.[14][15]
Neuroscience[edit]
Where it acts
No neuroimaging or functional studies of 2-AI have been conducted. Based on its pharmacological profile — selective norepinephrine release with α₂-adrenoceptor binding[2][11] — the primary neural target is the ascending noradrenergic system originating in the locus coeruleus. This nucleus projects to the prefrontal cortex, amygdala, hippocampus, and thalamus, modulating arousal, vigilance, and attention.
The wakefulness, alertness, and appetite suppression reported by users are consistent with elevated noradrenergic tone across these regions. Weak DAT activity[2] predicts minimal direct engagement of the mesolimbic mesolimbic pathway, consistent with reports of stimulation without pronounced euphoria.
Why it matters
The most explanatory framework for 2-AI's cognitive effects is the Yerkes-Dodson inverted-U relationship between noradrenergic tone and performance: moderate norepinephrine enhancement improves attention and working memory, while excess produces anxiety and cognitive impairment. 2-AI's α₂-adrenoceptor binding may act as a pharmacological brake that keeps noradrenergic activation within the productive range — though without functional assay data, this remains theoretical.[11]
Several fundamental questions remain unanswered. The functional status of 2-AI at α₂-adrenoceptors — agonist, antagonist, or partial agonist — would have opposite consequences for both the stimulant experience and cardiovascular risk. Whether NAT2 metabolic polymorphism translates to meaningfully different effect intensity or duration has not been tested. The unusually short 1–2 hour duration may reflect rapid enzymatic clearance, autoreceptor-mediated feedback, or both — but no human pharmacokinetic data exist to distinguish these possibilities.
Subjective Effects[edit]
The experiential character of 2-AI is shaped by its selective noradrenergic pharmacology. Users describe a clean, functional stimulation dominated by physical activation and mental alertness, without the emotional warmth or prosocial openness produced by serotonin-active compounds.[2] At lower doses, effects center on wakefulness and mild cognitive sharpening; higher doses intensify physical stimulation and cardiovascular awareness. Set, setting, and individual NAT2 metabolizer status likely modulate both intensity and duration, though this variability has not been formally studied.[6]
The closest experiential comparators from user reports are benzylpiperazine and low-dose amphetamine — compounds producing alertness-driven stimulation without pronounced euphoria or emotional depth.[4] The notably short duration and reported compulsive redosing urge distinguish 2-AI from longer-acting stimulants and create a usage pattern that amplifies cardiovascular risk.
Effect Grid
Clear stimulant effects emerge — pronounced wakefulness, appetite suppression, and physical stimulation define the experience. Visual acuity enhancement and music enhancement may be noted. Thought acceleration and analysis enhancement become reliably present, along with moderate motivation enhancement.
Cardiovascular activation becomes noticeable — heart rate perception changes and mild blood pressure elevation are expected from NET-mediated norepinephrine release. Excessive sweating and dehydration sensation may begin. Bruxism is possible but not prominent.
The compulsive redosing urge may emerge as effects wane quickly (total duration 1–2 hours). Aftereffects include cognitive fatigue, motivation suppression, and mildly depressed mood lasting 2–4 hours. NAT2 slow acetylators may experience effects closer to the strong range at these doses.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Music enhancement
Dry mouth · Pupil dilation · Dehydration sensation · Excessive sweating · Body high · Heart rate perception changes · Insomnia · Muscle tension · Physical fatigue · Restlessness · Bruxism · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Pain suppression · Abnormal heartbeat · Nausea · Sexual arousal suppression · Dizziness
Excessive sweating · Body high · Heart rate perception changes · Insomnia · Muscle tension · Physical fatigue · Restlessness · Bruxism · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Pain suppression · Nausea · Sexual arousal suppression · Dizziness
Information processing enhancement · Analysis enhancement · Thought organization · Cognitive fatigue · Cognitive flexibility · Introspection enhancement · Openness enhancement · Motivation suppression · Memory enhancement · Thought deceleration
Cognitive flexibility · Introspection enhancement · Openness enhancement · Motivation suppression · Memory enhancement · Thought deceleration
Emotional enhancement · Emotional lability · Anhedonia · Simultaneous emotions
Emotional susceptibility · Flow state · Craving
Timeline
Gradual emergence of alertness and mild peripheral stimulation. Heart rate awareness and subtle wakefulness increase as norepinephrine release begins.
Full noradrenergic activation — pronounced wakefulness, appetite suppression, physical stimulation, and cognitive enhancement. Cardiovascular effects (heart rate, blood pressure elevation) are most apparent.
Rapid decline in stimulant effects. Irritability, restlessness, and compulsive redosing urge may emerge as norepinephrine levels normalize. Cardiovascular effects subside.
Post-stimulant recovery period characterized by cognitive fatigue, depressed mood, and motivation suppression rather than a pleasant afterglow. Insomnia may persist despite fatigue.
⚠ Avoid driving or operating machinery until cognitive fatigue has fully resolved — impaired concentration may persist 2–4 hours after subjective effects end.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- amphetamine · methylphenidate · cathinones
Toxicity
Acute toxicity
No experimental toxicity data exist for 2-AI in any species. The only systematic assessment is a computational modeling study that applied seven prediction platforms to estimate 2-AI's toxicological profile.[5]
Key predictions include an oral LD₅₀ range of 150–560 mg/kg in rats (the wide spread reflecting substantial model disagreement), an 80% probability of cardiovascular toxicity, and a 66% probability of pulmonary involvement. The predicted hERG inhibition IC₅₀ of 391.7 µM suggests low risk of heart rhythm disturbances at pharmacological doses.[5]
safety citation needed All values above are computational predictions only — no experimental confirmation exists. The wide LD₅₀ range should not be treated as a reliable safety margin.
The predicted cardiovascular toxicity is consistent with 2-AI's pharmacology: norepinephrine release produces increased heart rate, elevated blood pressure, and vasoconstriction. These effects are expected to scale with dose.
Class toxicity
The related compound MDAI has established LD₅₀ values in rats: 28.33 mg/kg subcutaneously and 35 mg/kg intravenously, with death occurring through blood clotting failure and brain swelling.[14] These values should not be extrapolated to 2-AI — MDAI targets the SERT and produces serotonin-type toxicity, while 2-AI targets the NET and is expected to produce cardiovascular toxicity instead.[2]
Liver toxicity
No direct liver toxicity data exist for 2-AI. The related compound MDAI has shown cell-damaging potential in human liver cells.[16] The finding that 2-AI resists liver oxidation and depends entirely on NAT2 acetylation for clearance[6] raises a theoretical concern about accumulation in slow metabolizers, but this has not been investigated.
Fatal cases
No published case reports describe death attributed to 2-AI alone. Two fatalities involving the structural analog MDAI involved polysubstance use — one with 5-EAPB,[17] one with 2-MAPB.[18] Neither isolates aminoindane toxicity from co-ingestant effects.
Psychological risks
No controlled data on psychological adverse effects exist. User reports describe irritability, cognitive fatigue, and depressed mood during the aftereffect period.[4] The short duration and reported compulsive redosing urge suggest a pattern of repeated administration that could amplify both psychological distress and cardiovascular strain.
The noradrenergic mechanism predicts vulnerability to anxiety, agitation, and panic at excessive doses — effects characteristic of sympathetic overdrive. No case reports of psychosis or lasting psychological harm specifically attributed to 2-AI have been published.
Tolerance and dependence
No controlled studies address tolerance or dependence for 2-AI. Community-sourced estimates — tolerance building with repeated use, approximately 5-day half-life, 1.5-week full reset — are not verified against primary literature.[4]
2-AI's weak DAT activity predicts lower reinforcing potential than amphetamine or methcathinone.[2] No self-administration or reward-seeking studies have tested this prediction directly.
Cross-tolerance with other noradrenergic agents (amphetamine, methylphenidate, cathinones) is expected based on shared mechanism but has not been experimentally confirmed.
Drug interactions
Three interaction classes carry the highest risk, all inferred from 2-AI's norepinephrine releasing mechanism:
Serotonin syndrome: Despite 2-AI's weak serotonin activity, aminoindanes "may pose a significant risk of serotonin syndrome at high doses or when combined with other drugs".[3] Combinations with MDMA, MAOIs, SSRIs, and SNRIs are particularly hazardous — additive monoamine effects could produce dangerous overheating, muscle rigidity, and autonomic instability.
Sympathomimetic crisis: Combining 2-AI with other stimulants — cocaine, amphetamines, or cathinones — risks profound norepinephrine excess. Cocaine blocks norepinephrine reuptake while 2-AI forces norepinephrine release, creating a dual-mechanism surge that could cause severe blood pressure elevation, heart rhythm disturbance, or coronary vessel spasm.
Seizure threshold: Combination with tramadol is particularly concerning — tramadol independently lowers seizure threshold, and additive norepinephrine effects compound the risk.
safety citation needed Existing severity ratings for tramadol, MDMA, and cocaine interactions are mechanistically plausible but not supported by published 2-AI-specific case reports. No documented fatalities involving 2-AI combined with any of these substances have been reported.
The MDAI interaction creates complementary monoamine release — MDAI targeting serotonin, 2-AI targeting norepinephrine — increasing risk of both serotonergic and noradrenergic toxicity.
Contraindications
No substance-specific contraindication data exist. The following are inferred from 2-AI's noradrenergic pharmacology:
inferred
Cardiovascular disease — Norepinephrine-driven increases in heart rate, blood pressure, and vessel constriction make pre-existing heart conditions, high blood pressure, or irregular heartbeat absolute contraindications. Computational models predict an 80% probability of cardiovascular toxicity.[5]
MAOI use — Monoamine oxidase inhibitors prevent the breakdown of released norepinephrine, dramatically amplifying cardiovascular and neurological effects. This is an absolute contraindication for all monoamine releasers.
Seizure disorders — Noradrenergic stimulants lower seizure threshold.
Pregnancy and lactation — No reproductive toxicity data exist. Sympathomimetic stimulants as a class are associated with reduced blood flow to the uterus. Avoidance is the default recommendation.
NAT2 slow acetylator status — Individuals who are slow NAT2 metabolizers face meaningfully higher blood levels of 2-AI from the same dose.[6] This pharmacogenomic consideration is unique to 2-AI among recreational stimulants.
Liver impairment — Although 2-AI does not use standard liver enzyme pathways, its sole clearance route (NAT2 acetylation) is hepatic. Severe liver disease could further impair an already variable clearance mechanism.
Harm Reduction[edit]
Forms & Identification
2-AI typically appears as the hydrochloride salt — a white to off-white powder. The free base is a liquid at room temperature, so any solid form encountered in practice is almost certainly a salt preparation. Reagent testing can help distinguish 2-AI from more dangerous substitutes, but aminoindanes are uncommon enough that standard colorimetric reagents may produce unfamiliar results. Quantitative testing through drug checking services provides the most reliable identification for a substance this rarely encountered.
Guidelines
- Test every batch with reagent kits and, ideally, a drug checking service — 2-AI is uncommon enough that mislabeling or substitution is a realistic concern
- Start with a low dose and wait the full duration before considering redosing — the short timeline creates a strong impulse to re-administer before previous effects have resolved
- Set a firm redosing limit before the session begins and communicate it to anyone present
- Stay hydrated but avoid excessive water intake — sympathomimetic stimulants can mask thirst cues
- Monitor heart rate if possible; discontinue use if heart rate feels uncomfortably rapid or irregular
- Avoid use in hot environments — noradrenergic stimulation impairs heat regulation
- Ensure food is available for the aftereffect period, as appetite typically returns with a rebound effect
Set & Setting
2-AI's short duration and reported compulsive redosing urge make setting especially important. Having a defined endpoint — deciding in advance on a maximum number of doses — reduces the risk of repeated administration that compounds cardiovascular strain. The purely stimulant profile means 2-AI is unlikely to produce the psychological crises associated with psychedelics, but anxiety and agitation can escalate at higher doses or with repeated redosing, particularly in stimulating or stressful environments.
Aftercare & integration. The comedown from 2-AI typically involves irritability, cognitive fatigue, and low mood lasting several hours. Prioritize sleep — the noradrenergic rebound can make falling asleep difficult, but rest is the most effective recovery tool. Light, easily digestible food helps restore depleted energy.
Avoid compensating for the comedown with additional stimulants, caffeine, or alcohol. If depressed mood persists beyond 24–48 hours or becomes distressing, consider reaching out to a mental health professional.
Recovery & Support
2-AI's short duration and compulsive redosing profile can establish patterns of repeated use that escalate over time. If use has become frequent or difficult to control, structured support may help. SMART Recovery and similar programs offer evidence-based frameworks for managing stimulant use patterns. For immediate support, crisis lines and harm reduction organizations can provide confidential guidance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, severe headache, seizure, loss of consciousness, or body temperature that feels dangerously hot through clothing indicate a medical emergency. Extreme agitation or confusion beyond what stimulant effects would explain also warrants emergency help.
Immediate steps:
- Call emergency services immediately if any of the above signs are present
- Move the person to a cool, quiet space
- Do not restrain unless there is immediate danger of self-harm
- If the person is unconscious, place them in the recovery position
- Monitor breathing and pulse while waiting for help
What to tell the dispatcher: Name the substance (2-aminoindane / 2-AI), estimated amount taken, time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for norepinephrine-releasing stimulants. Emergency treatment is supportive — cooling, sedation with benzodiazepines, and blood pressure management.
Legal Status[edit]
2-Aminoindane is not controlled under any United Nations convention. The UNODC has confirmed that "none of the aminoindanes are under international control".[19] National scheduling varies by jurisdiction and largely reflects responses to the novel psychoactive substance wave that followed mephedrone prohibition in 2010.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled (federal) | Not listed in DEA schedules. May be prosecutable under the Federal Analogue Act (21 U.S.C. § 813) if sold for human consumption, as a structural analog of amphetamine. |
| United Kingdom | Controlled (blanket ban) | Covered under the Psychoactive Substances Act 2016, which prohibits production, supply, and possession with intent to supply of any psychoactive substance not specifically exempted.[19] |
| China | Controlled | Scheduled since October 2015 under NPS-specific legislation.[19] |
| Sweden | Controlled / Hazardous substance | Designated by the Public Health Agency in June 2019.[19] |
| Austria | Controlled | Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG).[19] |
| Canada | Unscheduled | Not listed in CDSA schedules. Analog provisions may apply depending on prosecution interpretation. |
| Australia | Status unclear | Not specifically scheduled. State-level analog provisions may capture 2-AI.citation needed |
Analog act considerations
In jurisdictions with structural analog legislation (United States, Canada, Australia), 2-AI's structural relationship to amphetamine creates legal exposure even without specific scheduling. The Federal Analogue Act requires that a substance be "substantially similar" in chemical structure to a Schedule I or II substance and intended for human consumption. 2-AI's characterization as a conformationally restricted amphetamine analog[10] strengthens the structural similarity argument, though prosecution depends on the specific facts of each case.
references
- [1] ^abcdNichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (1990) Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). — Journal of Medicinal Chemistry PMID:1967651
- [2]
- [3] ^abcdPinterova N, Horsley RR, Palenicek T (2017) Synthetic Aminoindanes: A Summary of Existing Knowledge. — Frontiers in Psychiatry doi:10.3389/fpsyt.2017.00236
- [4]
- [5] ^abcdJurowski K, Frydrych A (2026) First toxicity profile of 2-aminoindane and N-Methyl-2-aminoindane using in silico multi-approach. — Toxicology in Vitro doi:10.1016/j.tiv.2025.106149
- [6]